REMARKS

The applicant provisionally elects with traverse the claims of Group I (claims 1-9, 11, 16-

19) for prosecution on the merits.

The examiner has stated that restriction under 35 U.S.C. 121 and 372 is required

because the inventions of Group I and II are not so linked as to form a single general

inventive concept under PCT Rule 13.1. The examiner has argued that the "special

technical feature" uniting the method and product/kit claims is the detection of the IGF2

gene in cattle. The applicant respectfully disagrees. The special technical feature is *not* the detection of *IGF2* gene in cattle, but the detection of a specific polymorphism in the

IGF2 gene cattle. This special technical feature is not disclosed in the prior art- none of

the prior art references cited teach the detection of this polymorphism in cattle. This

special technical feature is an element of all of the claims of Group II and Group I.

Therefore, all claims do have the same or corresponding technical feature, which is a

novel polymorphism in the $\emph{IGF}2$ gene.

Claim 12 has been amended to more clearly define the invention claimed, more

specifically, a kit that determines the genotype of a bovine animal at position 150 of

SEQ ID NO: 1 in the $\emph{IGF2}$ gene. Claims 18 and 19 have also been amended to identify

the SEQ ID NO: as being SEQ ID NO: 1.

Favourable consideration and withdrawal of the restriction requirement is respectfully requested.

Respectfully submitted,

Heenan Blaikie LLP.

HEENAN BLAIKIE LLP

South Tower, Royal Bank Plaza, Suite 2600

200 Bay Street PO Box 185 Toronto, Ontario

CANADA M5J 2J4 (416) 643-6813

HBdocs - 4884254v1

6